A Wall Street Journal story on Dec. 21 vividly chronicles the battle between two rival technologies to chart genetic differences in clinical trials. Industry leader Affymetrix is losing ground and market share to Illumina. The story notes that the Illumina role in a key scientific paper on inflammatory bowel disease…more...
After starting out at Wyeth and Hoffmann-La Roche, Kevin Keim has spent 30 years in the industry. He’s assisted or run 400 trials. Most recently, Keim joined INC Research, a mid-sized contract research organization (CRO). He’s a pharmacologist who previously served (among other things) as the CEO of Vela Pharmaceuticals…more...
The topic of adaptive clinical trial designs is the most powerful and far-reaching issue now percolating through the community. Adaptive designs promise something for everyone. First and foremost, as a keystone element of the agency’s unfunded Critical Path agenda, adaptive trials could burnish the lagging reputation of the FDA as…more...
The Cleveland Clinic picked Steven Nissen to be interim head of cardiovascular medicine, anointing formal replacement for Eric Topol, a vehement critic of the pharmaceutical industry. (Topol is leaving the Cleveland Clinic for its crosstown rival, Case Western University.) Nissen is unlikely to view the industry through rose-colored glasses: he…more...
Insightful Corp. is rolling out the beta software for S-Plus. Insightful calls the program its next major release for statistical data analysis and predictive analytics. The beta program will be conducted on S-Plus 8 Enterprise Developer and will be available until August 31, 2006. New features under consideration include: language…more...
MicroStrategy, a leading worldwide provider of business intelligence software and SPSS, a leading worldwide provider of predictive analytics software, today announced that they have a strategic alliance. The two companies will engage in joint business development and cooperative marketing programs. By combining MicroStrategy’s advanced business intelligence technology with the leading-edge…more...
Insightful Corp. reported a 23 percent increase in revenues for the fourth quarter of 2005. Revenues for the year were up 18 percent. The company’s tools are used in a variety of industries, but it does not specify the proportion derived from helping drug companies analyze data in clinical trials.…more...
SAS announced revenue growth of 10 percent, to $1.7 billion. The news release didn’t mention revenues from life sciences. more...
December 3, 2008
United BioSource talks about resources (its own and others) for adaptive trials.
Cytel and Tourtellotte Consulting join forces to design trials and drug supply needs for adaptive protocols.
As life science organizations consider adaptive clinical trial designs, the process, technology and operational aspects are complex. What to consider.
Can your clinical data warehouse combine genotyping data, clinical data and demographic data? And analyze it in a reproducible way? A conversation with Waban.
Cytel and Tourtellotte consulting have integrated two important applications.
In describing a new Phase III trial, Napo Pharmaceuticals touts its adaptive approach. Will other sponsors stoke investor interest using the anticipation surrounding adaptive trials?
Organizations
Conferences
Info & Opinion
